Think.Health
VC Fund
Fürstenfeldbruck, Germany
Think.Health is a VC fund in Fürstenfeldbruck focused on Health Care and Biotechnology. Think.Health invests as a boutique risk-taker in healthcare ventures. We continuously seek innovations and disruptive business models in digital healthcare, medical technologies and health service providers,
- Total investments:
- 36
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Think.Health invests in
Stages Think.Health invests in
Countries Think.Health invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Round size
- Seed
- $1.1M–$7.6M
- Series A
- $3.6M–$28M
Investment Focus
Industry
- Health Care 13 (36%)
- Biotechnology 7 (19%)
- Medical Device 5 (14%)
- Medical 4 (11%)
- Health Diagnostics 3 (8%)
Stage
- Seed 11 (31%)
- Series A 7 (19%)
- Series B 2 (6%)
- Series C 2 (6%)
- Series D 1 (3%)
Country
- Germany 16 (44%)
- United States 2 (6%)
- France 1 (3%)
- Switzerland 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Dr. Florian Kainzinger
Managing Partner & Founder
|
Managing Partner & Founder | Total investments: 2 | Find email | |
|
Rob Hamilton
Senior Vice President Of Sales
|
Senior Vice President Of Sales | Total investments: 0 | Find email | |
Dr. Michael Ruoff
Partner
|
Partner | Total investments: 0 | Find email | |
Nils Bottler
Venture Partner
|
Venture Partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Robeaute
|
Robeaute is a research and development agency that develops neurosurgical microrobots that can adapt to different types of medical evidence. | $28M / Series A / Jan 14, 2025 | |
Inflammatix
|
Inflammatix develops novel molecular diagnostics for acute infections and sepsis that work by 'reading' the immune system. It is a molecular diagnostics company developing rapid tests that read the immune system to resolve major clinical and public health challenges.They are initially focused on developing tests for acute bacterial andviral infections, and sepsis based on patent-pending biomarkers exclusively licensed from Stanford University. | $57M / Series E / Sep 12, 2024 | |
Sphingotec GmbH
|
SphingoTec is a biomaker company that develops and markets in vitro diagnostic solutions for novel and proprietary blood-based protein biomarkers. They also develop microtiter plates, which are a standard tool in analytical research and diagnostic testing laboratories. They develop biomakers to address diagnostically underserved critical careconditions such as acute kidney injury, sepsis, and acute heart failure. | $5.5M / Series C / Aug 08, 2024 | |
Myo
|
Myo is a communication platform for the care market.they are proud to have designed a product with Myo that brings together people in care.their team is always looking for new talents who would like to work on a product for better care. | $8.6M / Series A / Jan 31, 2024 | |
Selfapy
|
Selfapy offers a therapy support tool that helps recognize negative patterns of thought and train new behavior. Selfapy is your guided, self-help online course against depression with a personal psychologist as a companion. | $7.5M / Venture - Series Unknown / Feb 17, 2023 | |
Navignostics
|
Our mission is to identify the ideal treatment to battle each cancer patient’s disease and reduce suffering throughout their journey.At Navignostics we characterize tumors using spatial single-cell proteomics. We use our unique capabilities to identify a cancer treatment that will optimally fight each patient’s tumor. We also accelerate cancerdrug development by providing key insights into drug mechanisms and tumor features for companion diagnostic development.Our highly robust and reliable technology and our leading data analytics position us ideally to enable precision cancer diagnostics for patients and to provide services to pharma and biotech partners.This way we help people suffering from cancer by making more drugs available and by finding the right one for every patient. | $7.6M / Seed / Nov 09, 2022 | |
Vara
|
Vara develops a breast cancer screening platform powered by AI for radiologists, allowing them to focus on finding cancer early. While we provide. Vara also provides remote mammography reading services to those that lack the radiologists. Vara's mission is to make affordable diagnostics available all over the world by designing machinelearning-powered workflows that users love to work with. | $4.5M / Series A / Oct 25, 2022 | |
anvajo
|
Originally started at TU Dresden, anvajo can now look back on several years of innovative research and successful product development with uninterrupted growth. As part of the business expansion and ongoing team building, anvajo moved into its new headquarters in Dresden in January 2020. On 1300 m² practically all areas, including development,production and support functions are united under one roof. | $17.3M / Series A / Oct 19, 2022 | |
|
Inflammatix
|
Inflammatix develops novel molecular diagnostics for acute infections and sepsis that work by 'reading' the immune system. It is a molecular diagnostics company developing rapid tests that read the immune system to resolve major clinical and public health challenges.They are initially focused on developing tests for acute bacterial andviral infections, and sepsis based on patent-pending biomarkers exclusively licensed from Stanford University. | $102M / Series D / Mar 16, 2021 | |
|
Myo
|
Myo is a communication platform for the care market.they are proud to have designed a product with Myo that brings together people in care.their team is always looking for new talents who would like to work on a product for better care. | Series A / Oct 25, 2020 | |
| See all 36 investments → | |||
Co-Investors
Mountain Partners
4 deals together
Northpond Ventures
4 deals together
Atlantic
3 deals together
Axel Springer Plug and Play Accelerator
3 deals together
BONVENTURE
3 deals together
D1 Capital Partners
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Think.Health invest in?
Think.Health invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Seed and Series A stage. Most of the 36 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Think.Health's check size?
Think.Health typically joins rounds of $1.1M–$7.6M at Seed and $3.6M–$28M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Think.Health participates in.
How do I contact Think.Health?
Public channels for Think.Health include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Think.Health?
The team at Think.Health includes Dr. Florian Kainzinger (Managing Partner & Founder), Rob Hamilton (Senior Vice President Of Sales) and Dr. Michael Ruoff (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
